AdvaMed warns of gaps in product access under CMS bidding scheme
This article was originally published in Clinica
US medtech industry association AdvaMed has voiced concerns over the competitive acquisition programme initiated by the Centers for Medicare and Medicaid Services (CMS). The association claims that the programme could limit the accessibility of products.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.